Post-Authorisation Safety Study (PASS) MA25101: An Observational Cohort Study of the Safety of Brentuximab Vedotin in the Treatment of Relapsed or Refractory CD30+ Hodgkin Lymphoma and Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma (ARROVEN)

28/02/2013
02/07/2024
EU PAS number:
EUPAS3583
Study
Finalised
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

MA25101_Post-Authorisation Safety Study (PASS)_Amendment 2 w MPI change

English (986.79 KB - PDF) View document
Updated protocol

MA25101 Protocol Amend 4 2017-01-27

First published: 22/02/2024
English (472.02 KB - PDF) View document
Study results
Study results

FINAL Takeda ARROVEN PASS_CSR_v3.0_27Nov2019

English (1.1 MB - PDF) View document

MA25101 - Abstract

English (693.93 KB - PDF) View document
Study report
Other information